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New antimalarials are urgently needed. We have shown that tetrahydroquinoline (THQ) protein farnesyl-
transferase (PFT) inhibitors (PFTIs) are effective against the Plasmodium falciparum PFT and are effective at
killing P. falciparum in vitro. Previously described THQ PFTIs had limitations of poor oral bioavailability and
rapid clearance from the circulation of rodents. In this paper, we validate both the Caco-2 cell permeability
model for predicting THQ intestinal absorption and the in vitro liver microsome model for predicting THQ
clearance in vivo. Incremental improvements in efficacy, oral absorption, and clearance rate were monitored by
in vitro tests; and these tests were followed up with in vivo absorption, distribution, metabolism, and excretion
studies. One compound, PB-93, achieved cure when it was given orally to P. berghei-infected rats every 8 h for
a total of 72 h. However, PB-93 was rapidly cleared, and dosing every 12 h failed to cure the rats. Thus, the in
vivo results corroborate the in vitro pharmacodynamics and demonstrate that 72 h of continuous high-level
exposure to PFTIs is necessary to kill plasmodia. The metabolism of PB-93 was demonstrated by a novel
technique that relied on double labeling with a radiolabel and heavy isotopes combined with radiometric liquid
chromatography and mass spectrometry. The major liver microsome metabolite of PB-93 has the PFT Zn-
binding N-methyl-imidazole removed; this metabolite is inactive in blocking PFT function. By solving the X-ray
crystal structure of PB-93 bound to rat PFT, a model of PB-93 bound to malarial PFT was constructed. This
model suggests areas of the THQ PFTIs that can be modified to retain efficacy and protect the Zn-binding
N-methyl-imidazole from dealkylation.
Malaria remains a huge issue in global health. Snow et al.
estimate that there were 515 million cases of malaria in 2002
(21), and the WHO estimates that there are approximately 2
million deaths due to Plasmodium falciparum each year (26)
Despite a vigorous campaign to roll back the impact of ma-
laria, the rates of morbidity and mortality from malaria are
actually increasing (21). Much of the reason for the increasing
morbidity and mortality is the increased resistance to the low-
cost drugs that are available in the developing world (18) Thus,
new inexpensive drugs are urgently needed to address the
global burden of malaria.
Protein farnesyltransferase (PFT) inhibitors (PFTIs) are
promising drugs for the treatment of malaria, and a number of
different scaffolds have been shown to inhibit the growth of the
malaria parasite in vitro and in vivo (2–4, 7–9, 11, 12, 16, 19, 20,
27–31). In our previous publications, we showed that tetrahy-
droquinoline (THQ) PFTIs inhibit malaria growth (5, 16).
THQ PFTIs are cidal and not static, as evidenced by the in-
ability of parasites to recover in washout experiments in vitro
and after sufficient exposure in the Plasmodium berghei mouse
model (16). The initial THQ compounds studied had poor oral
bioavailabilities and underwent rapid clearance from animals.
For this reason, it was necessary to implant subcutaneous
pumps to administer stable levels of THQ PFTIs to demon-
strate proof-of-concept killing of Plasmodium berghei in mice
(16). The in vitro cultivation of P. falciparum in the presence of
increasing concentrations of THQ compounds led to parasites
with 10- to 13-fold increased resistance to THQs (5, 16). The
resistant parasites were determined to contain mutations en-
coding amino acid changes in the PFT active site that led to 10-
to 13-fold reduced sensitivities of the enzyme to THQ inhibi-
tion. This established with near certainty that PFT is the target
of the THQ compounds.
Novel antimalarial drugs are urgently needed for the devel-
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oping world because the developing world bears most of the
morbidity and the mortality burden. Drugs for the developing
world must be inexpensive and easily administered. The prod-
uct profile of an antimalarial drug useful for the developing
world includes oral bioavailability, a maximum 3 days of ther-
apy for cure, and once- or twice-daily dosing (17). The in vitro
pharmacodynamics of THQ PFTIs demonstrated that 3 days of
exposure at levels 10 to 50 times the concentration that led to
50% growth inhibition (the 50% effective dose [ED50]) was
necessary for the complete killing of P. falciparum (16). As
noted above, the initial THQ compounds had issues with poor
oral bioavailability and rapid clearance. Thus, for THQ PFTIs
to become useful as antimalarials, compounds with improved
oral absorption and reduced clearance must be found.
This paper reports on studies of the issues surrounding THQ
oral absorption and clearance. Results that validate the find-
ings from in vitro models that were used to address these issues
are presented. THQs with improved drug-like properties that
lead to oral efficacy in 3 days in a rat model of malaria are
reported. In addition, a structural model of THQ PFTIs in the
active site of the P. falciparum PFT is presented. This model
shows where additional modifications in THQ can be made to
retain its potency and improve its metabolism.
MATERIALS AND METHODS
Plasmodium strains. The P. falciparum strains used in this study were 3D7 (a
chloroquine-sensitive strain from a case of airport-associated malaria in The
Netherlands) and K1 (a chloroquine-resistant, pyrimethamine-resistant strain
from Thailand). Strain 3D7 was provided by Pradipsinh Rathod from the Uni-
versity of Washington. P. falciparum strain K1 and P. berghei isolate NK65 (used
for rodent malaria experiments) were obtained from the MR4 Unit of the
American Type Culture Collection (Manassas, VA).
P. falciparum culture. Strains of P. falciparum were cultured in vitro by using
the experimental techniques described by Trager and Jensen (23). Cultures were
maintained in RPMI 1640 (Sigma, St. Louis, MO) with 2 mM L-glutamine, 25
mM HEPES, 33 mM NaHCO3, 20 g/ml gentamicin sulfate, and 20% (vol/vol)
heat-inactivated human type A-positive plasma (RP-20P). Type A-positive eryth-
rocytes were obtained from laboratory donors, washed three times with RPMI
1640, resuspended in 50% RPMI 1640, and stored at 4°C. The parasites were
grown in 10 ml of 2% (vol/vol) hematocrit–RP-20P in 50-ml flasks under a 5%
CO2, 5% O2, and 90% N2 atmosphere.
P. falciparum ED50 determination. Ten microliters of PFTI in solution was
added to each well of a 96-well plate, followed by the addition of 190 l of an
asynchronous P. falciparum culture at a parasitemia and a hematocrit of 0.5%
each. PFTI solutions were prepared by diluting 20 mM THQ PFTI in dimethyl
sulfoxide (DMSO) by 200-fold with RP-20P for the highest concentration (a 100
M stock gave a final assay concentration of 5 M) and then performing further
serial dilutions in RP-20P. The plates were flushed with 5% CO2, 5% O2, and
90% N2 and were then incubated at 37°C for 48 h. [8-3H]hypoxanthine (0.3 Ci,
20 Ci/mmol; American Radiolabeled Chemicals) in 30 l RP-20P was added to
the cultures, and the cultures were incubated for an additional 24 h. Cells were
harvested onto glass fiber filters with a cell harvester (Inotech Biosystems Inter-
national, Inc., Rockville, MD), and the radioactivity incorporated into the par-
asites was counted on a Chameleon 425-104 multilabel plate counter (Hidex Oy,
Turku, Finland). The background level detected with uninfected erythrocytes
was subtracted from the data. The level of 3H incorporation into infected eryth-
rocytes with 1 l DMSO vehicle alone represents 100% malaria growth. ED50
values, the effective dose that reduces growth by 50%, were determined by linear
regression analysis of the plots of the level of [3H]hypoxanthine incorporation
versus the concentration of compound. Each compound was tested in duplicate,
and the mean value is shown; individual measurements differed by less than
threefold.
P. falciparum PFT IC50 determination. The PFT assay used to determine the
inhibitor concentration that caused 50% enzyme inhibition (IC50) is based on a
PFT 3H scintillation proximity assay (SPA; TRKQ7010; Amersham Biosciences
Corp., Piscataway, NJ) (3). SPA works on the basis of the principle that the
radioactivity in close proximity to avidin-coated beads containing scintillant emits
more light than the radioactivity throughout the solution. The biotinylated pep-
tide is prenylated with [3H]farnesyl when PFT is not inhibited, the biotin-pep-
tide-[3H]farnesyl binds to avidin-coated beads containing scintillant, and light is
emitted. Assays were carried out in assay buffer (pH 7.5, 50 mM HEPES, 30 mM
MgCl2, 20 mM KCl, 5 mM dithiothreitol, 0.01% Triton X-100), 1 M human
lamin B carboxy-terminus sequence peptide (biotin-YRASNRSCAIM), and 1
Ci [3H]farnesylpyrophosphate (specific activity, 15 to 20 Ci/mM; Amersham) in
a total volume of 50 l which included 1 l of PfPFT inhibitor solution in DMSO
and 5 l of partially purified PfPFT. Assays performed in the absence of inhibitor
PfPFT and PfPFT were included as positive and negative controls, respectively.
The reaction mixtures were incubated at 37°C for 60 min and terminated by
addition of 70 l of assay STOP solution (Amersham) and 5 l SPA beads. The
assay mixture was incubated at room temperature for 30 min. The assay results
were counted on a plate Chameleon 425-104 multilabel counter (Hidex Oy) that
detected the photons emitted by the scintillation beads bound to biotin-peptide-
[3H]farnesyl. IC50 values were calculated by linear regression analysis of the plots
of the amount of radioprenylation versus the concentration of compound.
THQ compound synthesis. The THQ compounds cited in this publication are
listed below. We will describe the synthesis and characteristics of these THQs in
a separate report (1a). For Caco-2 cell/blood level measurements (Fig. 1) the
compounds used for the plot included LN-16, LN-20, LN-25, LN-29, PB-17,
PB-26, PB-27, PB-37, PB-43, PB-48, PB-54, PB-93, PB-102, and BS-03. See Table
6 for the results for the PB-54 analogs with R5 modifications, in which the results
are given for the following 35 analogs: PB-69, PB-86, PB-87, PB-88, PB-89,
PB-90, PB-91, PB-92, PB-93, PB-94, PB-95, PB-96, PB-97, PB-98, PB-99, PB-
100, PB-101, PB-102, PB-104, PB-105, PB-106, PB-107, PB-108, PB-109, PB-110,
PB-111, PB-112, PB-113, PB-114, PB-126, PB-127, PB-139, PB-140, and PB-141.
To examine the effect of different linkages of the R1 pyridyl, the following
compounds were compared: BMS-404683, PB-80, and PB-81. The structures of
all of the compounds are shown in the supplemental material.
Synthesis of [13C, 15N]PB-93. The analog of PB-93 containing a bromine
instead of cyano at the 6 position of the THQ ring [4-({[6-bromo-1-(3-methyl-
3H-imidazol-4-ylmethyl)-1,2,3,4-tetrahydro-quinolin-3-yl]-(pyridine-2-sulfonyl)-
amino}-methyl)-piperidine-1-carboxylic acid methyl ester; 10 mg; prepared by
methods analogous to those described elsewhere (16), except that the imidazole
rather than the imidazolium trifluoroacetate salt was used] was dissolved in 1 ml
of anhydrous dimethyl formamide (Aldrich) in a glass vial with a Teflon septum-
lined screw cap. Argon was bubbled through the solution for 10 min by inserting
a needle through the cap. [13C, 15N]Zn(CN)2 (see below) (3 mg) was added, and
argon was passed through the solution for an additional 10 min. Pd(PPh3)4 (1
mg; Aldrich) was added, followed by brief bubbling with argon. The mixture was
heated in the capped vial under argon in an oil bath at 120°C for 16 h. The
mixture was allowed to cool, and water and ethyl acetate were added. The
organic layer was concentrated to dryness, and the residue was purified on a C18
reverse-phase high-pressure liquid chromatography column, as described previ-
ously (16), to give 2.7 mg of the desired product (the structure was confirmed by
FIG. 1. Correlation of peak plasma levels and Caco-2 cell perme-
ability measurements of THQ compounds. The means of three values
of the maximum plasma concentrations after dosing of THQ com-
pounds at 50 mg per kg to mice versus Caco-2 cell permeability levels
(Papp) for 14 THQ compounds with which both tests were performed
are shown. The best-fit line is shown with the slope of the line and the
statistical significance of the linear relationship (r2 value and P value,
respectively; Prism GraphPad software).
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1H-nuclear magnetic resonance and electrospray ionization mass spectrometry
[MS]).
[13C, 15N]Zn(CN)2 was made as follows. [13C, 15N]KCN (50 mg; Cambridge
Isotopes) was added with stirring to a solution of ZnSO4(H2O)7 (1.1 g) in 0.34
ml of water. The mixture was stirred for 30 min at room temperature, and the
precipitated [13C, 15N]Zn(CN)2 was collected by centrifugation. The solid was
washed twice by resuspension of the pellet in 0.5 ml of water, followed by
recentrifugation. The solid [13C, 15N]Zn(CN)2 was dried under vacuum in a
desiccator containing a beaker of P2O5.
Synthesis of [14C]PB-54, [14C]PB-43, and [14C]PB-93. [14C]PB-54, [14C]PB-
43, and [14C]PB-93 were made as described above for [13C, 15N]PB-93 by using
[14C]Zn(CN)2 (American Radiochemicals, Inc., St. Louis, MO). [14C]PB-54 and
[14C]PB-43 were made by using 25 mg of the aromatic bromide and 5.3 mg
of [14C]Zn(CN)2 (110 Ci/mol). [14C]PB-93 was made by using 10 mg of the
aromatic bromide and 3 mg of [14C]Zn(CN)2 (25 Ci/mol). The radiolabeled
compounds were judged to be radiochemically pure by thin-layer chromato-
graphic analysis on a silica plate with fluorography to visualize the radioactivity
by using X-ray film.
Caco-2 cell drug permeability assay. For Caco-2 cell permeability assays (from
the apical [A] side to the basolateral [B] side of the cell monolayer), Caco-2 cells
(clone TC7; obtained from Ming Hu, Washington State University, Pullman)
were cultured on a semipermeable membrane to form a highly functionalized
epithelial barrier (24). The apparent permeability of small molecules across these
cells represents a well-established in vitro model of in vivo intestinal wall trans-
port that has often demonstrated a good correlation with intestinal absorption in
humans. Caco-2 cells (4  105) were plated on laminin-coated cell culture
membrane inserts (3.0-m pore diameter, 25-mm diameter; Nalge; Nunc). Con-
fluence was reached 3 to 4 days after the cells were plated, and the monolayers
were used for the experiments 19 to 21 days postseeding. Transepithelial elec-
trical resistance values were taken by using a Millicell-ERS apparatus (Millipore,
Bedford, MA), and [3H]mannitol transport was monitored for each well to
determine the integrity of the monolayers before the drug transport assay. After
the monolayers were rinsed twice with assay buffer, they were incubated at 37°C
in assay buffer (Hanks buffered salt solution, 5 mM HEPES, pH 7.4) for 30 min.
During the assays, all volumes amounted to 0.56 ml on the A side of the
monolayer and 1.5 ml on the B side. Stock compounds in DMSO (2 mM) were
diluted in assay buffer to a final concentration of 50 M and applied to the donor
(A) side of the membrane. The monolayer membranes were incubated at 37°C
with shaking. At 60 min, 20-l samples were taken from the receiver (B) side.
The 20-l samples were extracted with an equal volume of acetonitrile contain-
ing 1 pmol internal standard. The samples were then centrifuged and the super-
natant was loaded directly into the vials for liquid chromatography-MS (LC/MS)
analysis. The apparent permeability coefficient (Papp, cm/s · 106) for each
compound was calculated as [(1.5  CB60)/3,600]  (1/{4.2 [(CA0  CA60)/2] 
[(CB0  CB60)/2]}), where CXY indicates the concentration (C) in the A or B
chamber (X) at the indicated time (Y) (in minutes) (e.g., CB60 is the concentra-
tion in the B chamber at 60 min), 1.5 is the volume of the B chamber (in ml),
3,600 is 60 min (in seconds), and 4.2 is the area of the Caco-2 cells (in cm2). For
assays from the B side to the A side, the assays were performed as described
above; however, the compounds were placed on the B side of the chamber at
time zero, and the calculations were performed as described above, but with B
simply substituted for A and vice versa.
Microsome metabolism. Liver microsome metabolism assays were performed
with female pooled microsomes (BD Biosciences, San Jose, CA). The reaction
mixtures (400 l) contained pH 7.4 0.1 M potassium phosphate buffer, 3 mM
MgCl2, 1 mM EDTA, 1 mM NADP, 5 mM glucose-6-phosphate, 1 U/ml
glucose-6-phosphate dehydrogenase (Sigma), and 0.5 mg/ml liver microsomes.
Each reaction mixture was incubated at 37°C for 10 min, and then 2 l of THQ
as a 200 M stock in DMSO was added to give a final solution of 1 M THQ in
the reaction mixture. At each time point, samples of the reaction mixtures were
stopped with 3 the volume of acetonitrile containing an internal standard. The
THQ concentration and the metabolites were quantified for each time point by
LC/MS analysis.
Ames test. The Ames test was performed by the CEREP Corp. (Redmond,
WA) in 96-well plates by using two Salmonella enterica serovar Typhimurium
strains, strains TA98 and TA100 (15). TA98 detects frame shifts, and TA100
detects base substitutions leading to missense mutations. These two strains were
incubated with various concentrations of PB-93 and four reference compounds
(quercetin, streptozotocin, aminoanthracene, and mitomycin C) for 96 h in liquid
culture, after which bacterial growth was measured spectrophotometrically by
using a pH indicator that changes color in response to the acidification of the
medium due to bacterial growth. Mutants were detected by a shift from auxo-
trophy by using histidine-free medium. Metabolic activation was achieved by
using the rat liver S9 microsome fraction. The compounds in both bacterial
strains were tested with and without S9 at four concentrations (5, 10, 50, and 100
M; higher customized concentrations were also used) in 48 wells. To prevent
false-negative results due to bactericidal or bacteriostatic effects, a bacterial
cytotoxicity assay was conducted in parallel at the same concentrations. No
cytotoxicity of PB-93 or its metabolites for the Salmonella strains was observed.
Receptor binding activity. The ability of PB-93 at 10 M to displace a radio-
labeled ligand from a panel of 50 receptors and pharmacologically active ion
channels and transporters was tested at CEREP Corp. The following receptors,
ion channels, and transporters were tested: adenosine A1, adenosine A2A, aden-
osine A3, adrenergic receptor alpha1 (nonselective), adrenergic receptor alpha2
(nonselective), adrenergic receptor beta1, dopamine D1, dopamine D2S, -ami-
nobutyric acid (GABA; nonselective), GABA BZD (central), GABA Cl-channel,
histamine H1, histamine H2, melatonin MT1 (ML1A), muscarinic receptor M1,
muscarinic receptor M2, muscarinic receptor M3, serotonin 5-HT1A, serotonin
5-HT1B, serotonin 5-HT2A, serotonin 5-HT3, serotonin 5-HT5A, serotonin
5-HT6, serotonin 5-HT7, angiotensin-II AT1, bradykinin B2, chemokine CCR1,
chemokine CXCR2 (interleukin-8B), cholecystokinin CCK1 (CCKA), endothe-
lin ETA, galanin GAL2, melanocortin MC4, neurokinin NK2, neurokinin NK3,
neuropeptide Y Y1, neuropeptide Y Y2, neurotensin NTS1 (NT1), opioid and
opioid-like delta2 (DOP), opioid and opioid-like kappa (KOP), opioid and
opioid-like mu (MOP), opioid and opioid-like NOP (ORL1), somatostatin sst
(nonselective), vasoactive intestinal peptide VPAC1 (VIP1), vasopressin V1a,
Ca2 channel L (verapamil site) (phenylalkylamines), K channel KV, K chan-
nel SKCa, Na channel site 2, dopamine transporter, and norepinephrine trans-
porter. The decrease in ligand binding was expressed as a percentage and was
considered significant when a 50% decrease in ligand binding was observed at
10 M PB-93.
Animal PK and ADME studies. (i) mouse oral PK/ADME studies. For mouse
oral pharmacokinetic (PK)/absorption, distribution, metabolism, and excretion
(ADME) studies, three female BALB/c mice (ages, 8 to 10 weeks) were used in
each group. Each group received a test compound at a dose of 50 mg/kg of body
weight dissolved in 3% ethanol (EtOH)–7% Tween 80–90% normal saline by
oral gavage. Blood plasma samples were taken at the designated time points by
tail bleeding. The samples were frozen at 20°C. The test compounds were
extracted from the blood plasma samples by using acetonitrile with an internal
standard. A standard mix of all test compounds was prepared for comparison and
quantification. The samples were quantified by LC/MS analysis.
(ii) Rat oral PK/ADME studies. For rat oral PK/ADME studies, three female
Sprague-Dawley rats (ages, 10 to 12 weeks) were used in each group. Each group
received test compound at a dose of 50 mg/kg dissolved in 3% EtOH–7% Tween
80–90% normal saline by oral gavage. Blood plasma samples were taken from the
saphenous vein at the designated time points and were treated as described
above for extraction and quantification. The blood samples were sent to a clinical
laboratory (Phoenix Laboratories, Everett, WA) at the end of dosing for deter-
mination of complete blood counts, electrolytes, and glucose concentrations for
kidney and liver function tests.
(iii) Rat i.v. PK/ADME studies. For rat intravenous (i.v.) PK/ADME studies,
three female Sprague-Dawley rats (ages, 10 to 12 weeks) catheterized in the
jugular vein were used in each group. Each group received test compound at a
dose of 2 mg/kg dissolved in 3% EtOH–7% Tween 80–90% normal saline in a
400-l volume through the jugular vein catheter. Blood plasma samples were
taken from the jugular vein catheter at the designated time points and were
treated as described above for extraction and quantification.
(iv) Rats with cannulated bile ducts. Experiments with rats with cannulated
bile ducts were performed at ABC Inc., Columbia, MO, according to the fol-
lowing protocol. Male Sprague-Dawley rats (approximate weight, 350 g each)
were cannulated in the jugular vein and the bile duct and were allowed to recover
from surgery for 1 week. Three animals each were dosed by oral gavage with 35
mg/kg of each compound dissolved in 3% EtOH–7% Tween 80–90% normal
saline with 80 Ci/kg radiotracer. The animals were monitored for 18 h; urine,
feces, and bile were collected; the cages were washed with methanol-water; and
the animals were autopsied. The radioactivity in each sample was measured by
liquid scintillation counting. Bile samples were subjected to LC and LC/MS with
MS/MS to determine the probable THQ PFTI metabolites of each peak.
Studies with P. berghei-infected rats. Five female Sprague-Dawley rats (ages,
10 to 12 weeks) were used in each group in studies with P. berghei-infected rats.
One group received PB-93 and one group received PB-102, each at 50 mg/kg
dissolved in 3% EtOH–7% Tween 80–90% normal saline, by oral gavage dose
every 8 h for 3 days. One group of control rats received a vehicle-only dose on
the same dosing schedule. All rats were infected by intraperitoneal injection with
4  107 erythrocytes parasitized with P. berghei NK65 6 days prior to dosing.
Parasitemia was determined by light microscopy of blood samples.
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X-ray crystallographic studies and modeling. Crystals of the FPT–PB-93 com-
plex was prepared by soaking PB-93 into preformed crystals by previously de-
scribed methods (22). X-ray diffraction data for the FPT–PB-93 complex were
collected on a Rigaku Fr-E generator equipped with Max-Flux optics and a
Raxis-IV image plate detector. With the detector set at 150 mm, data were
collected in 250 contiguous 0.30-degree oscillation images, each of which was
exposed for 300 s. The data were extended to a 2.23 Å resolution and had an
Rmerge value of 6.1% and 4.3-fold multiplicity. The structure was refined by using
CNX2002 software (Accelrys Inc.) to an Rfactor value of 18.9% and an Rfree value
of 22.0%. The electron density maps clearly showed the orientation of PB-93.
The stereochemistry of the THQ moiety in PB-93 was not able to be assigned
definitively from the electron density.
A homology model of malarial PFTase (PfPFT) was generated with the
MODELLER program by using the crystal structure of rat PFT complexed with
the nonsubstrate tetrapeptide inhibitor CVFM and farnesyl diphosphate (FPP) as
the template structure (Protein Data Bank entry 1JCR). The sequences of the two
subunits (subunits a and b) of PfPFT were obtained from the PlasmoDB database
(gene loci PFL2050w,a and chr11.glm_528,b) and aligned with the template with the
program T-COFFEE. Only regions for which there was reasonable reliability in the
alignment were included. The model of PfPFT comprises the following sequence
segments (the residue numbers of the corresponding segments of the rat PFT
subunits are given in parentheses): a, 72 to 164 (87 to 179) and 300 to 411 (184 to
283); b, 421 to 677 (71 to 315) and 806 to 896 (330 to 417). PfPFT and rat PFT share
23% identity and 53% similarity in the a subunit; the respective values for the b
subunit are 37 and 56%. The catalytic zinc ion, six structurally conserved water
molecules, and FPP were included in the model. The conformation of FPP was
considered flexible during the model calculations. For this purpose, the force-field
parameters for FPP were added to the MODELLER program force field on the
basis of the lipid parameters of the charmm27 force field. The model with the lowest
value of the objective function of the MODELLER program from 20 different
calculations was used for docking studies.
Protein structure accession number. The coordinates of the THQ moiety in
PB-93 have Protein Data Bank code 2R2L, but the unique identifier has not yet
been assigned.
RESULTS
Previously we have shown that THQ protein PFTIs are po-
tent inhibitors of PfPFT and block the growth of P. falciparum
in vitro and of P. berghei in the mouse model of malaria (16).
We have also established with virtual certainty that PFT is the
in vivo target of THQ compounds due to the association of
resistant parasites with active-site mutations in PFT that ren-
der the enzyme relatively resistant to THQs in vitro (5, 6).
The major issue with THQ PFTIs as potential therapeutics is
that they do not provide sufficient exposure after oral admin-
istration for effective therapy for malaria. In our previous pa-
per, it was necessary to administer THQ PFTIs through a
slow-release subcutaneous pump to show the proof of concept
in the P. berghei mouse model of malaria (16). In this report,
modified THQ PFTIs that give improved oral exposure for
therapy for malaria are described.
The Caco-2 cell permeability model is predictive of the
plasma levels of THQ PFTIs after oral administration. We
first sought an in vitro model for oral absorption of THQ
PFTIs and turned to the widely used Caco-2 cell permeability
model (24). In this model, human colon carcinoma Caco-2
cells are grown to a confluent monolayer in a chamber, and
after several weeks, tight junctions form and the cells recapit-
ulate many aspects of intestinal epithelial cells, including asym-
metrical A and B functional differences (24). Caco-2 cell per-
meability assays are typically carried out from the A to the B
direction (A-B) to reflect the orientation of the intestinal ep-
ithelial cells in the gastrointestinal tract (24). We compared the
in vitro Caco-2 cell permeability values for a series of THQ
PFTIs to measurements of peak plasma levels after oral dosing
of mice. We chose peak plasma levels rather than exposure
(area under the curve [AUC]) because exposure is more de-
pendent on clearance than peak plasma levels. As can be seen
in Fig. 1, higher Caco-2 values were correlated with higher
peak plasma levels of THQ PFTIs. As expected, this correla-
tion was not perfect, as first-pass metabolism and clearance
rates in the liver after oral dosing also affect peak plasma
concentrations. However, the significant linear relationship be-
tween Caco-2 cell permeability and peak plasma levels sup-
ports the use of Caco-2 cell permeability as a model for gas-
trointestinal absorption.
Oral absorption of THQ PFTIs is influenced by apparent
B-to-A pump activity and is improved by a 2-pyridyl substitu-
tion. In our initial series of THQ PFTIs with an N-methyl
(Me)-imidazole substitution at the R1 position (Fig. 2), we
FIG. 2. Structure of THQ PFTI (PB-93) with substituent defini-
tions. The structure of PB-93 THQ PFTI and the positions of groups
labeled R1 through R5 in the text, tables, and figures are shown.
TABLE 1. Relationship of R1 group to Caco-2 cell permeability
and AUC after oral administration
Compound R1 group
Caco-2 cell
permeability
(106 cm/s)
Peak plasma level
(M) after oral
administration
of 50 mg/kg to miceA to B B to A
LN-16 N-Me-imidazole 0.7 72.5 3.9
LN-20 N-Me-imidazole 0.2 52.1 1.1
LN-25 N-Me-imidazole 0.2 23.9 1.0
LN-29 N-Me-imidazole 0.3 53.0 0.8
PB-17 2-Pyridyl 0.2 50.1 0.15
PB-26 2-Pyridyl 2.3 12.1 9.8
PB-27 2-Pyridyl 1.6 73.3 5.7
PB-37 2-Pyridyl 8.0 67.1 15
PB-43 2-Pyridyl 12.4 45.5 13.6
Propranolol Standard 28.9 83.4 Well absorbed
Ranitidine Standard 0.3 5.6 Not well absorbed
Vinblastine Standard 0.1 41.9 Not well absorbed
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found that the Caco-2 A-B permeability was poor (Table 1).
This could be because of poor cellular permeability or due to
B-to-A active transport (24). To test whether the apparent low
Caco-2 cell A-B values for THQ PFTIs were due to asymmet-
ric transport from B to A, the same series of compounds was
tested for B-to-A Caco-2 cell permeability. Table 1 shows that
all compounds tested in this series with an R1 group of N-Me-
imidazole had very high levels of B-A transfer but extremely
low levels of A-B transfer. This suggests that a B-A transport
mechanism may be responsible for the poor permeability and
poor plasma levels of the N-Me-imidazole THQ PFTIs.
Some of the compounds with a 2-pyridyl R1 group had
improved Caco-2 cell A-B permeability and reduced B-A per-
meability; these compounds had improved plasma levels (Ta-
ble 1). Thus, it seems likely that THQ PFTIs with the 2-pyridyl
R1 group are less avidly pumped from B to A than the N-Me-
imidazole R1 group, favoring better intestinal absorption for
the 2-pyridyl R1 THQs.
A wide screen of variations of R1 failed to yield a substituent
that retained potency against PFT and P. falciparum cells ex-
cept for 2-pyridyl and N-Me-imidazole (1a). An example of
how sensitive the R1 substituent is to small changes that lead
to a loss of potency is given in Fig. 3. Even substitution of a
3-pyridyl or a 4-pyridyl at the R1 position led to the dramatic
loss of inhibitory activity against PfPFT and against P. falcip-
arum growth. Thus, we continued with the 2-pyridyl group for
further optimization of PK/ADME properties.
In vitro liver microsome metabolism correlates with in vivo
metabolism and the clearance of THQ PFTIs. In general, THQ
PFTIs were found to have relatively short half-lives in plasma
after either oral or i.v. administration. We did not perform
many i.v. administrations of the compounds because of our
ultimate goal of obtaining an orally active compound. Instead,
we obtained data for multiple compounds administered orally
by gastric lavage to mice and rats (Table 2). The same com-
pounds were studied to determine the rate of elimination by
liver microsomes in vitro (Table 2). Only one compound, that
is, BS-03, which has a phenyl group instead of a cyano group at
R4, had a significantly reduced metabolism in mouse and rat
microsomes. BS-03 also had a significantly reduced clearance
rate in mice and rats after oral dosing (oral clearance rate)
compared with the rates for the other compounds, which all
had rapid metabolism by microsomes. The oral clearance rate
is an imperfect measurement of clearance because it is also
dependent on the rate of absorption in the gastrointestinal
tract. Nonetheless, the data show that the in vitro microsome
metabolism rate correlates with the clearance rate of the com-
pounds in vivo. This suggests that in vitro the liver microsome
metabolism rate is a reasonable surrogate marker for clearance
rate in vivo.
Further support for this hypothesis comes from comparison
of metabolites that develop in vitro in liver microsomes and in
vivo in rodent plasma. With four compounds, we were able to
identify metabolites by LC/MS studies of supernatants after in
vitro rat and mouse microsome metabolism and in the plasma
from mice and rats dosed orally (Table 3). In some cases,
FIG. 3. Substitution of the 2-pyridyl R1 group with either 3-pyridyl or 4-pyridyl leads to a dramatic loss in potency against PFT (IC50) and P.
falciparum parasites (ED50). The structures of three THQ PFTIs demonstrating the effect of varying the R1 pyridyl group on the enzyme activity
(IC50) and the anti-P. falciparum growth activity (ED50) are shown.
TABLE 2. Comparison of microsome metabolism rate and exposure after oral administration of 50 mg/kg in mice and ratsa
Compound
Mice Rats
Microsome
metabolism
rate (t1/2b [min])
AUC
(M · min) Cmax (M)
Oral elimination
t1/2
c (min)
Microsome
metabolism
rate (t1/2 [min])
AUC
(M · min) Cmax (M)
Oral elimination
t
1/2
(min)
LN-16 3.4 273 3.9 30 16 325 3.4 26
PB-43 4.9 957 13.5 40 10.4 696 5.4 62
PB-93 5.8 221 4.2 18 14 1320 7.6 53
PB-102 5.1 280 5.4 27 18 2026 8.4 62
BS-03 98 942 5.0 88 165 810 4.1 106
a The values are the means for three animals.
b t1/2, half-life.
c This is not the true half-life of elimination of a compound, which is classically obtained by i.v. administration. The oral elimination rate is affected by the rate of
absorption.
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additional dehydrogenation of the primary metabolite oc-
curred in vivo but not in vitro. In one case, LN-16 in rats, the
primary metabolite identified in vitro (the OR3 group) was
different from the metabolite seen in plasma (2O). However,
in almost every case, the major metabolite identified in vivo
was also seen after in vitro microsome metabolism, supporting
in vitro liver microsome metabolism as a surrogate for in vivo
metabolism.
The bile duct-cannulated rat model confirms that THQ
PFTIs are metabolized in the liver. To further establish their
ADME characteristics, two radiolabeled THQ PFTIs were
dosed orally to rats whose bile ducts were cannulated. PB-43
and PB-54 were selected for these studies because they gave
measurable plasma levels after oral dosing of mice and rats.
These compounds were labeled at R4 with 14CNO, as it
seemed unlikely that the cyano R4 moiety would be cleaved
from the THQ ring and exchange of 6-Br on the THQ ring with
14CN could be carried out in the last synthetic step. After oral
gavage, the rats were monitored for 18 h and their urine and
feces were collected, and after autopsy, the level of recovery of
the radiolabel was tallied, as shown in Table 4. No adverse
reactions were noted, and the rats appeared to be healthy
throughout the dosing of the compound. Less than 5% of the
radioactivity was recovered in urine, suggesting that urinary
excretion was not likely a major mode of elimination for
THQs. The majority of label was recovered in the feces and
gastrointestinal tract, suggesting that much of the THQ either
was not absorbed or was excreted by the gastrointestinal tract.
At least 25% of each compound was absorbed, given the quan-
tity of radioactivity recovered in bile (Table 4). Excretion was
rapid, in that 80% of the radioactivity excreted in the bile
during the 18-h observation period was excreted in the first 6 h.
Blood levels of 1 to 3 g/ml of radiolabeled compound were
obtained for each compound (Table 5). The sizeable propor-
tion of the label that appeared in bile during the 18 h suggests
that much of the absorbed THQ is metabolized by the liver and
is excreted into the bile (Table 4).
The bile was subjected to LC, and each peak was analyzed by
LC-MS/MS. PB-43 was found to be oxidized at multiple places
throughout the molecule and secondary glucuronidation was
also observed (see Figure SA2 in the supplemental material).
Most of the metabolites of PB-54 were due to oxidation of the
tert-butyl group and often with secondary metabolism at the
tert-butyl group (see Figure SA3 in the supplemental material).
Thus, for these two compounds, the oxidation likely carried out
by cytochrome P450 enzymes was responsible for the rapid
clearance.
PB-54 analogs yield PB-93 with increased efficacy. Since the
metabolism of PB-54 occurred primarily on the tert-butyl (R5)
group and PB-43 was metabolized at many sites in the mole-
cule, we elected to study additional analogs of PB-54. Thirty-
five PB-54 analogs with groups at R5 that resulted in carbam-
ates, amides, ureas, and sulfonamides were synthesized. These
35 analogs were tested for PfPFT inhibition (IC50), anti-P.
falciparum growth activity (ED50), and Caco-2 cell permeabil-
ity (Table 6). Some of these were administered orally to rats,
and the plasma levels (the peak concentrations [Cmaxs]) and
exposure (AUC) of the compounds were obtained (Table 6).
The only class that retained Caco-2 cell permeability and rea-
sonable exposure in animals was the carbamate class of com-
pounds. Thus, we focused on improving the carbamate analogs
further.
Reducing the tert-butyl to isopropyl and ethyl and methyl
substituents led to a progressive and 10-fold improvement in
antiparasitic activity (ED50) and a moderate improvement of
the activity against PfPFT (IC50) (Table 7). The Caco-2 cell
permeability also decreased throughout this series, and there
was a concordant decrease in the exposure (AUC) to the
TABLE 3. Metabolic products detected from THQ compounds in vitro and in vivo
Compound
Metabolic product(s) detected in:
Mouse microsomes Mouse plasma after oral gavage Rat microsomes Rat plasma after oral gavage
LN-16 R3 R3, R3 O, R3  2O R3 2O
PB-37 O, R2 and R3 O, R2 and R3-4H, R3 O, R2 and R3 R2 and R3-4H
PB-43 O O, R2 and R3-4H O O, R2 and R3-4H
PB-54 R2 and R3 R2 and R3-4H, R3, O R2 and R3 R2 and R3-4H, (COO-t-butyl) O,
R3, O
TABLE 4. Recovery of radioactivity in BDC Rats after oral
administration of [14C]PB-43 or [14C]PB-54
Matrix
Mean % of administered dose
PB-43 group PB-54 group
Bile 27.1 26.2
Urine 1.6 4.3
Feces 33.7 26.7
Gastrointestinal tract with contents 40.3 18.2
Tissues/carcass NMa 9.7
Cage wash 0.7 7.1
Total 104 92.2
a NM, not measurable (below detection limit).
TABLE 5. Concentration of PB-43 or PB-54 in plasma and blood
cells of rats
Time
point (h)
Mean g base equivalents/g sample
PB-43 group PB-54 group
Plasma Blood cells Plasma Blood cells
0.5 1.38 0.566 1.50 0.442
1 1.36 0.493 2.01 0.909
2 0.723 0.344 2.14 1.030
3 0.237 0.221 2.20 0.821
4 NMa 0.073 1.92 0.729
6 NM 0.063 1.23 0.623
18 0.351 0.243 0.340 0.344
a NM, not measurable (below detection limit).
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compounds (Table 7) by moving from a tert-butyl to a methyl
substituent. Exposure (AUC) was greater in rats than in mice,
and this correlated with the more rapid metabolism of these
compounds by mouse liver microsomes compared with that by
rat liver microsomes. However, we were unable to identify the
metabolites of unlabeled PB-93 after liver microsome metab-
olism in vitro or in the plasma of rats and mice dosed orally
with PB-93.
The exposure of PB-93 after oral administration to rats is
shown in Fig. 4. By 8 h after administration, the amount of
PB-93 had fallen to barely detectable levels. Thus, it seemed
likely that PB-93 needed to be dosed at least every 8 h to show
efficacy.
PB-93 shows efficacy in the rat-P. berghei model of infection.
Rats instead of mice were chosen for a therapeutic trial of oral
PB-93 because the exposure in rats was much more than that
in mice (Table 7). Rats were infected with P. berghei, para-
sitemia was established for about 2% of erythrocytes, and then
the rats were treated with PB-93 at 50 mg per kg every 8 h for
3 days. By day 2 of therapy no parasites were demonstrable in
the PB-93-treated group, but the level of parasitemia persisted
at 1.4% in the untreated controls (Fig. 5). Although the level of
parasitemia decreased slightly in the controls treated with ve-
hicle only, the level of parasitemia remained significantly ele-
vated compared with that in PB-93-treated rats, which re-
mained parasite free on days 3 and 4. A few recrudescent
parasites were detected in one of five treated rats on days 5, 7,
and 14; but all the untreated rats remained parasitemic for the
entire 2-week observation period. This experiment was also
carried out with oral dosing every 12 h. Although an initial
reduction in the level of parasitemia was observed in rats dosed
every 12 h, once therapy was stopped, there was a recrudescent
parasitemia to higher levels than that in control rats (data not
shown). Thus, PB-93 shows promise for use for the oral ther-
apy of rats in the P. berghei model, even with only 3 days of
therapy, but constant exposure to the THQ PFTIs during this
time period is required to achieve a cure.
Metabolism of PB-93 leads to dealkylation of the N-Me-
imidazole-CH2 R3 group, leading to an inactive PFTI. With
unlabeled PB-93, no metabolites could be detected by LC/MS
after liver microsome metabolism or in the plasma of rats or
mice. To better define the metabolites of PB-93, we labeled the
CN at R4 with trace 14C or with a 50:50 mixture of unlabeled
CN and CN doubly labeled with 13C and 15N. This allowed us
TABLE 6. A series of 35 PB-54 analogs with modifications at R5 demonstrates that carbamates have the best
efficacy and PK/ADME properties
PB-54 analog Structure IC50 (nM) ED50 (nM)
Caco-2 cell
permeability
(106 cm/s)
Cmax (M)
after oral
administration
of 50 mg/kg
to rats
AUC (M · min)
after oral
administration
50 mg/kg
to rats
Carbamates 0.5–1.6 16–155 1.0–15.5 4.5–8.4 653–1,806
Amides 0.6–1.2 12–48 0.5–0.6 0 (1)a 0 (1)
Ureas 0.8–1.8 13–320 0.6–0.7 0 (1) 0 (1)
Sulfonamides 0.5–0.9 62–75 0.1–1.0 0 (1) 0 (1)
a Values in parentheses indicate the number of rats.
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to monitor the progressive metabolism of PB-93 by separation
using LC, followed by scintillation counting of chromatography
fractions. The radiolabeled peaks could be then studied by MS
by looking for split heavy-light metabolites that differed in
mass by 2 Da. Figure 6 demonstrates that as the parent mol-
ecule is metabolized during 10 to 30 min of exposure to liver
microsomes; there is a progressive accumulation of a peak that
elutes slightly later. The analysis of this peak by MS is shown
in the inset in Fig. 6. There is a 2-Da split peak at 470 and 472
Da that corresponds to the native and heavy atom versions of
PB-93 without the R3 N-Me-imidazole-CH2 (R3). This R3
metabolite has a very low ionization efficiency compared with
that of the parent molecule and was impossible to demonstrate
without the heavy atom labeling. Thus, the majority of the
metabolism of PB-93 dealkylates the R3 N-Me-imidazole-CH2
group.
Structure of rat PFT liganded with PB-93. We determined
the X-ray crystal structure of the PB-93–rat PFT complex to
2.23 Å, and although the density for the stereochemistry was
ambiguous, the density of PB-93 allowed us to clearly assign
the binding of the compound. On the basis of these coordi-
nates, the structure of PfPFT was modeled with PB-93 and is
shown in Fig. 7. In both PfPFT and rat PFT, there is a large
hydrophilic pocket which the carbamate R2 moiety fills. R2
essentially resides in the a2X part of the CaaX box binding site
of the protein. This large pocket explains the wide tolerance of
diversity in R2s of effective THQ PFTIs (see THQ PFTIs from
this paper and from the work of Bendale et al. [1a]). The
carbonyl group of the R2 carbamate hydrogen bonds with the
side chain of a serine (position 99 in rat PFT, position 449
in PfPFT), while the piperidine ring interacts with a Trp (po-
sition 102 in rat PFT, position 452 in PfPFT). The R1
2-pyridyl group folds back and stacks against the hydrophobic
farnesyl chain, and the nitrogen of the 2-pyridyl group hydro-
gen bonds with the phenol of Tyr (position 361 in rat PFT,
position 837 in PfPFT). This hydrogen bond explains the
selectivity for the 2-pyridyl group versus that for 3- and 4-pyr-
idyl groups at R1; the nitrogen of 4-pyridyl would be com-
pletely desolvated without compensation (Fig. 3). The R3 N-
Me-imidazole interacts with the Zn group of the enzymatic
pocket. The cyano R4 group extends into a relatively hydro-
phobic pocket. From this model, it is clear that changes in the
central core that could stabilize the R3 group of PB-93 are
allowed.
Lack of toxicity with THQ PFTIs. Throughout this work, rats
and mice were dosed with THQ PFTIs, and some doses led to
substantial exposures (Tables1 to 4 and 6; Fig. 4). Adverse
reactions were not observed with any of the compounds, and
the rodents appeared to be healthy throughout our dosing
studies. In addition, rats dosed with PB-93 at 50 mg/kg every
8 h or every 12 h (n 3 in each group) for 72 h did not develop
abnormalities in complete blood counts, white blood cell dif-
ferentials, electrolyte levels, glucose levels, renal functions,
liver enzyme levels, or cholesterol levels. PB-93 tested negative
for mutatgenesis in the two mutant/microsome-activated Ames
assays for the prediction of genotoxicity. Ten micromolar con-
centrations of PB-93 were tested against a panel of 50 recep-
tors associated with pharmacological effects and were negative
for binding to the 47 receptors tested. Significant binding was
only observed for the V1a vasopressin receptor (81% inhibi-
tion at 10 M), the M1 muscarinic receptor (64%), and the M2
muscarinic receptor (77%). These results indicate only a min-
imal potential for off-target effects with either series. Thus, the
THQ PFTIs appeared to be nontoxic in rodent models during
short-term exposure and in in vitro models of toxicity.
DISCUSSION
An optimal antimalarial for the developing world should
achieve a cure in 3 days or less with once- or twice-a-day oral
dosing (17). We tested previously reported PFTIs and found
that only the THQ PFTIs discovered at Bristol-Myers Squibb
(14) have promising anti-P. falciparum activities (16) (data not
shown). However, further development of THQ PFTIs as an-
timalarials was hindered by poor oral absorption and rapid
clearance. In this paper, we describe our progress toward un-
derstanding and overcoming the pharmacokinetic liabilities of
the first group of THQ PFTIs under study as antimalarials.
The THQ PFTIs that we have found to be the most effective
against the parasite and against PfPFT have an N-Me-imid-
FIG. 4. Plasma exposure after oral dosing with PB-93. The mean
levels in the plasma of three rats (in micromolar) with the standard
errors of the means at various time points after oral gavage with 50
mg/kg of PB-93 are shown.
FIG. 5. Efficacy study with PB-93 in P. berghei-infected rats. The
mean parasitemia (as the percentage of red blood cells parasitized) for
five rats and the standard errors of the means are shown. The times on
the x axis are in days, and day 0 is the start of treatment. Rats were
infected with P. berghei 6 days prior to day 0. Treatment was with 50
mg/kg PB-93 by oral gavage every 8 h or with vehicle only by oral
gavage every 8 h for a total of 72 h on days 0 to 3, as shown.
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azole group in the R1 position (Fig. 2) (1a). In order to help
predict the ability of these THQ PFTIs to be absorbed though
the gastrointestinal tract, we used the well-established Caco-2
in vitro cell permeability model. Unfortunately, the THQ com-
pounds with N-Me-imidazole at R1 were more permeable in
Caco-2 cells in the B-to-A direction than in the A-to-B direc-
tion (Table 1), suggesting they would not be well absorbed
orally due to efflux. In our hands, the B-A values were higher
for every compound tested, even the very permeable propran-
olol control compound. However, the ratio of B-A versus that
of A-B was very high when compounds contained the N-Me-
imidazole group at R1 and was similar to that of vinblastine, a
control drug that is known to be pumped from the B to the A
side by P-glycoprotein (10, 24). Many compounds with the
second most efficacious R1 group, 2-pyridyl, overcame this
difference in B-A versus A-B permeability (Table 1). Of note,
the A-B permeability correlates with peak plasma levels (Fig.
1). Taken together, these results suggest that the THQ com-
pounds with N-Me-imidazole at R1 are pumped from the B to
the A side of Caco-2 cells. This probably also occurs in the
intestine, explaining the low plasma levels of the THQs with
N-Me-imidazole at R1. This pumping maybe carried out by
P-glycoprotein transporters, which are well-described B-A
drug pumps in intestinal epithelial and Caco-2 cells (10, 24). By
testing compounds with different R1 substituents, we were
unable to find THQs, other than those with 2-pyridyl at R1,
that retained favorable A-B Caco cell permeability with suffi-
cient anti-P. falciparum activity (1a). Thus, we focused on
THQs with 2-pyridyl at R1 for further study.
The other major issue with THQs was their rapid clearance
from the circulation. Three lines of evidence, presented in this
report, suggest that this clearance is due to cytochrome P450
metabolism, probably in the gut and/or the liver (13, 25). First,
the metabolism rates in the liver microsomes correlated with
clearance after oral dosing (Table 2). The only THQ com-
pound (compound BS-03) with significant stability to liver mi-
FIG. 6. PB-93 cyano derivatives labeled with 14C and with 13C and 15N and their OR3 metabolites in liver microsome studies. The upper left
diagram shows PB-93 and the R3 and R5 groups of the structure. The graph below shows the radiochromatogram of 14C-labeled PB-93 standard
(STD) and 14C-labeled PB-93 metabolized by rat liver microsomes for 10 and 30 min. PB-93 consisted of a 50:50 mixture of an unlabeled CN group
and a CN group doubly labeled with 13C and 15N, such that the metabolites could be identified by a 2-Da split peak. By 30 min, the major
radioactive peak elutes later than the PB-93 standard. MS of this major metabolite peak (inset) reveals split peaks with a mass difference of 2 Da
at 470.3 and 472.2 Da. These masses correspond to PB-93 minus the R3 N-Me-imidazole-CH2 heavy and light versions. Several other metabolites
that had 2-Da split peaks are identified (see, e.g., 0 and OR3-R5 on the chart) but are minor radiotraces compared to the OR3 peak.
3668 VAN VOORHIS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 August 1, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
crosome metabolism also had significantly longer clearance
times in rats and mice. Second, the metabolites detected in the
in vitro liver microsome metabolism of THQ PFTIs correlated
closely with those observed in the plasma of orally dosed mice
and rats (Table 3). Third, the metabolites of the labeled THQs
administered orally to rats are rapidly excreted in the bile
(Table 4; see Figures SA2 and SA3 in the supplemental ma-
terial). The observed THQ metabolites are the result of well-
known oxidoreductive and dealkylation transformations car-
ried out by cytochrome P450 metabolism enzymes (Table 4;
see Figures SA2 and SA3 in the supplemental material). Sev-
eral THQs with N-Me-imidazole at R1 are potent binders of
human cytochrome P450 3A4 (data not shown); however, we
have not explored this further with the series of compounds
with 2-pyridyl at R1. We have not determined if the binding of
these THQ PFTIs to the 3A4 enzyme is accompanied by the
metabolism of the compounds or whether they are competitive
inhibitors of 3A4. Given the dominance of cytochrome P450
3A4 in human drug metabolism, it seems likely that to
improve the exposure of THQs after oral dosing, additional
stabilization of the THQs is necessary for effective antima-
larial therapy.
We found two leads (compounds PB-43 and PB-54) that had
improved oral exposure and that were metabolized signifi-
cantly in vitro and in vivo. PB-43 was oxidized on multiple
substituents, and PB-54 was primarily oxidized at the R2 tert-
butyl group (see Figures SA2 and SA3 in the supplemental
material). The oxidation of the PB-54 R2 group was greatly
reduced by conversion of the tert-butyl group (compound PB-
54) to a methyl group (compound PB-93). Compound PB-93
had the additional advantage of a 3-fold improvement in en-
zyme activity and a 10-fold improvement in cellular activity
(Table 7). Despite the absence of detectable metabolites from
PB-93, the half-life of liver microsome metabolism was in-
creased by only 40% and the elimination time was actually
reduced compared with that for PB-54 (Table 7).
To detect metabolites for compound PB-93, it was necessary
to use a radiolabeled tracer and heavy atom-labeled PB-93 in
liver microsome assays. These assays demonstrated that re-
moval by dealkylation of the R3 N-Me-imidazole-CH2 group
generated the major metabolite of PB-93. This metabolite has
a substantial reduction in ionization efficiency by MS com-
pared with that of parent compound PB-93, making it very
difficult to detect it by the use of unlabeled compound. Indeed,
it seems likely that R3 dealkylation of THQ PFTIs would have
been more generally observed, but these metabolites are not
readily apparent due to poor ionization in the MS instrument.
These metabolites are predicted to be devoid of activity against
PfPFT, as the R3 N-Me-imidazole is a direct ligand for the
Zn2 in the active site of PFT (Fig. 7). We have made a series
of THQs with other potential R3 Zn-binding moieties, and all
have 100-fold reduced potencies against PFT and the para-
sites compared with that of compounds with N-Me-imidazole
at R3. Thus, it seems unlikely that we can get significant inhi-
bition of PFT by THQs without the R3 N-Me-imidazole. We
have now begun to synthesize a novel series of compounds to
help reduce the R3 N-Me-imidazole-CH2 dealkylation.
The potent activity of PB-93 against plasmodial cells allowed
us to show the oral efficacies of THQ PFTIs. The administra-
tion if 50 mg/kg of PB-93 orally every 8 h for 3 days cleared P.
berghei parasites from rats after an infection had been estab-
lished. It was necessary to use the rat model of malaria rather
than the mouse model due to the rapid clearance of PB-93 and
other THQs in mice compared with in rats. The rat model has
limitations, in that the level of parasitemia remains low after
infection. In this case, all rats in the control group had persis-
tent parasitemia throughout the therapeutic trial and PB-93-
treated rats cleared their parasitemia after 2 days of therapy.
Although these are encouraging results, we believe that we
need to identify compounds with further improved pharmaco-
logical properties to provide sustained blood levels at lower
doses and to have a lower dosing frequency.
To date, no toxicity has been observed in rats or mice re-
ceiving short-term therapy with THQ PFTIs. Additionally,
studies of plasma biochemical markers and blood cell levels
after 3 days of oral PB-93 administration to rats showed no
FIG. 7. Modeled structure of PfPFT with PB-93. Two representations of the PfPFT protein are shown (left, stick model; right, surface model)
with the bound PB-93 structure (center small molecule in the center of both panels). The models are based on the X-ray crystal structure of the
rat PFT with PB-93; many of the active-site residues of the rat PFT and the PfPFT are conserved. The R3 N-Me-imidazole group complexes with
the zinc ion (green sphere). The R1 2-pyridyl group packs against the farnesyl group, and the 2-nitrogen group hydrogen bonds to a Tyr phenol.
The R3 group is located in a large space, which explains why diverse R3 groups are allowed; but specific interactions occur here, too, such as the
hydrogen bonding of the carbonyl group of the R2 carbamate. The cyano R4 group fits into a pocket that is obvious from the surface model.
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abnormalities. These observations suggest that 3-day therapy
with THQ is not toxic in rodents. Pharmacological profiling of
PB-93 has demonstrated that it has few receptor, ion channel,
or transporter issues. An Ames screen of PB-93 with or without
microsome transformation was negative for genotoxcity. The
toxicities of the class of PFTI drugs for cancer chemotherapy
include myelosuppression and gastrointestinal intolerance, but
these toxicities generally occur only late during 21-day cycles of
PFTI therapy and not at earlier times (1). All of this informa-
tion taken together suggests that 3-day THQ PFTI antimalaria
therapy will be tolerated well.
The binding coordinates of PB-93 with rat PFT and the
model of PB-93 binding to PfPFT (Fig. 7) suggest that sub-
stantial changes in the central core of THQ that will retain
PfPFT inhibition can be made. Thus, changes that are pre-
dicted to stabilize R3 dealkylation will be studied for enzyme
inhibition, efficacy against parasites, Caco-2 cell A-to-B per-
meability, and liver microsome metabolism. We hope to find
compounds with predicted improvements in oral exposure
while retaining their antimalarial potencies. These in vitro pre-
dictors will allow us to rapidly prioritize THQ PFTIs for in vivo
PK/ADME and efficacy experiments. We have defined both
the pharmacodynamics of exposure necessary to achieve cure
and the molecular details of the metabolism of THQ PFTIs.
We can now rationally design and improve the THQ PFTIs to
optimize the class for effective oral malaria therapy.
ACKNOWLEDGMENTS
This work was supported by the W. M. Keck Foundation Center on
Microbial Pathogens at the University of Washington, the Medicines
for Malaria Venture (MMV), and National Institutes of Health grant
AI054384 (to M.H.G.). O.H. was a fellow of the German Academy of
Natural Scientists Leopoldina (BMBF-LPD 9901/8-77). The work of
Aaron Riechers, ABC Inc., and CEREP is gratefully acknowledged.
We appreciate the helpful advice of Kenneth E. Thummel, Univer-
sity of Washington Department of Pharmaceutics; Alan E. Rettie,
University of Washington Medicinal Chemistry; William N. Charman,
Monash University Department of Pharmaceutics; Solomon Nwaka,
formerly of MMV and currently of WHO/TDR; Ian Bathurst, MMV;
J. Carl Craft, MMV; Win E. Gutteridge, MMV; Simon Campbell,
MMV; and the entire MMV ESAC group.
REFERENCES
1. Basso, A. D., P. Kirschmeier, and W. R. Bishop. 2006. Lipid posttranslational
modifications. Farnesyl transferase inhibitors. J. Lipid Res. 47:15–31.
1a.Bendale, P., S. Olepu, P. K. Suryadevara, V. Bulbule, K. Rivas, L. Nallan, B.
Smart, K. Yokoyama, S. Ankala, P. R. Pendyala, D. Floyd, L. J. Lombardo,
D. K. Williams, F. S. Buckner, D. Chakrabarti, C. Verlinde, W. C. Van
Voorhis, and M. H. Gelb. Second generation tetrahydroquinoline-based pro-
tein farnesyltransferase inhibitors as anti-malarials. J. Med. Chem., in press.
2. Carrico, D., J. Ohkanda, H. Kendrick, K. Yokoyama, M. A. Blaskovich, C. J.
Bucher, F. S. Buckner, W. C. Van Voorhis, D. Chakrabarti, S. L. Croft, M. H.
Gelb, S. M. Sebti, and A. D. Hamilton. 2004. In vitro and in vivo antimalarial
activity of peptidomimetic protein farnesyltransferase inhibitors with im-
proved membrane permeability. Bioorg. Med. Chem. 12:6517–6526.
3. Chakrabarti, D., T. Da Silva, J. Barger, S. Paquette, H. Patel, S. Patterson,
and C. M. Allen. 2002. Protein farnesyltransferase and protein prenylation in
Plasmodium falciparum. J. Biol. Chem. 277:42066–42073.
4. Eastman, R. T., F. S. Buckner, K. Yokoyama, M. H. Gelb, and W. C. Van
Voorhis. 2006. Thematic review series: lipid posttranslational modifications.
Fighting parasitic disease by blocking protein farnesylation. J. Lipid Res.
47:233–240.
5. Eastman, R. T., J. White, O. Hucke, K. Bauer, K. Yokoyama, L. Nallan, D.
Chakrabarti, C. M. J. Verlinde, M. H. Gelb, and W. C. Van Voorhis. 2005.
Resistance to a protein farnesyltransferase inhibitor in Plasmodium falcipa-
rum. J. Biol. Chem. 10:13554–13559.
6. Eastman, R. T., J. White, O. Hucke, K. Yokoyama, C. L. M. J. Verlinde,
M. A. Hast, L. S. Beese, M. H. Gelb, P. K. Rathod, and W. C. Van Voorhis.
2007. Resistance mutations at the lipid substrate binding site of Plasmo-
dium falciparum protein farnesyltransferase. Mol. Biochem. Parasitol.
152:66–71.
7. Fucik, K., K. Kettler, J. Wiesner, R. Ortmann, D. Unterreitmeier, J. Krauss,
F. Bracher, H. Jomaa, and M. Schlitzer. 2004. 2-(Arylpropionylamino)- and
2-(arylacryloylamino)benzophenones: farnesyltransferase inhibition and an-
timalarial activity. Pharmazie 59:744–752.
8. Gelb, M. H., W. C. Van Voorhis, F. S. Buckner, K. Yokoyama, R. Eastman,
E. P. Carpenter, C. Panethymitaki, K. A. Brown, and D. F. Smith. 2003.
Protein farnesyl and N-myristoyl transferases: piggy-back medicinal chemis-
try targets for the development of antitrypanosomatid and antimalarial ther-
apeutics. Mol. Biochem. Parasitol. 126:155–163.
9. Glenn, M. P., S. Y. Chang, C. Horney, K. Rivas, K. Yokoyama, E. E. Pusateri,
S. Fletcher, C. G. Cummings, F. S. Buckner, P. R. Pendyala, D. Chakrabarti,
S. M. Sebti, M. Gelb, W. C. Van Voorhis, and A. D. Hamilton. 2006. Struc-
turally simple, potent, Plasmodium selective farnesyltransferase inhibitors
that arrest the growth of malaria parasites. J. Med. Chem. 49:5710–5727.
10. Hunter, J., B. H. Hirst, and N. L. Simmons. 1993. Drug absorption limited
by P-glycoprotein-mediated secretory drug transport in human intestinal
epithelial Caco-2 cell layers. Pharm. Res. 10:743–749.
11. Kettler, K., J. Wiesner, K. Fucik, J. Sakowski, R. Ortmann, H. M. Dahse, H.
Jomaa, and M. Schlitzer. 2005. 2-(Aminoacylamino)benzophenones: farne-
syltransferase inhibition and antimalarial activity. Pharmazie 60:677–682.
12. Kettler, K., J. Wiesner, K. Silber, P. Haebel, R. Ortmann, I. Sattler, H. M.
Dahse, H. Jomaa, G. Klebe, and M. Schlitzer. 2005. Non-thiol farnesyltrans-
ferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophe-
nyl)-2 furyl]acrylic acid amides and their antimalarial activity. Eur. J. Med.
Chem. 40:93–101.
13. Kolars, J. C., P. Schmiedlin-Ren, J. D. Schuetz, C. Fang, and P. B. Watkins.
1992. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human
small bowel enterocytes. J. Clin. Investig. 90:1871–1878.
14. Lombardo, L. J., Camuso, A., J. Clark, K. Fager, J. Gullo-Brown, J. T. Hunt,
I. Inigo, D. Kan, B. Kolowitz, F. Lee, K. McGlinchey, L. Qian, C. Ricca, G.
Rovnyak, S. Traeger, J. Tokarski, D. K. Williams, L. I. Wu, Y. Zhao, V.
Manne, and R. S. Bhide. 2005. Design, synthesis and structure-activity rela-
tionships of tetrahydroquinoline-based farnesyltransferase inhibitors. Bioorg.
Med. Chem. Lett. 15:1895–1899.
15. Maron, D. M., and B. N. Ames. 1983. Revised methods for the Salmonella
mutagenicity test. Mutat. Res. 113:173–215.
16. Nallan, L., K. D. Bauer, P. Bendale, K. Rivas, K. Yokoyama, C. P. Horney,
P. R. Pendyala, D. Floyd, L. J. Lombardo, D. K. Williams, A. Hamilton, S.
Sebti, W. T. Windsor, P. C. Weber, F. S. Buckner, D. Chakrabarti, M. H.
Gelb, and W. C. Van Voorhis. 2005. Protein farnesyltransferase inhibitors
exhibit potent antimalarial activity. J. Med. Chem. 48:3704–3713.
17. Nwaka, S., and A. Hudson. 2006. Innovative lead discovery strategies for
tropical diseases. Nat. Rev. Drug Discov. 5:941–955.
18. Olliaro, P. 2005. Drug resistance hampers our capacity to roll back malaria.
Clin. Infect. Dis. 41(Suppl. 4):S247–S257.
19. Ortmann, R., J. Wiesner, A. Reichenberg, D. Henschker, E. Beck, H.
Jomaa, and M. Schlitzer. 2003. Acyloxyalkyl ester prodrugs of FR900098
with improved in vivo anti-malarial activity. Bioorg. Med. Chem. Lett.
13:2163–2166.
20. Reichenberg, A., J. Wiesner, C. Weidemeyer, E. Dreiseidler, S. Sanderbrand,
B. Altincicek, E. Beck, M. Schlitzer, and H. Jomaa. 2001. Diaryl ester
prodrugs of FR900098 with improved in vivo antimalarial activity. Bioorg.
Med. Chem. Lett. 11:833–835.
21. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The
global distribution of clinical episodes of Plasmodium falciparum malaria.
Nature 434:214–217.
22. Strickland, C. L., P. C. Weber, W. T. Windsor, Z. Wu, H. V. Le, M. M.
Albanese, C. S. Alvarez, D. Cesarz, J. del Rosario, J. Deskus, A. K. Mallams,
F. G. Njoroge, J. J. Piwinski, S. Remiszewski, R. R. Rossman, A. G. Taveras,
B. Vibulbhan, R. J. Doll, V. M. Girijavallabhan, and A. K. Ganguly. 1999.
Tricyclic farnesyl protein transferase inhibitors: crystallographic and calori-
metric studies of structure-activity relationships. J. Med. Chem. 42:2125–
2135.
23. Trager, W., and J. B. Jensen. 1976. Human malaria parasites in continuous
culture. Science 193:673–675.
24. van Breemen, R. B., and Y. Li. 2005. Caco-2 cell permeability assays to
measure drug absorption. Expert. Opin. Drug Metab. Toxicol. 1:175–185.
25. Watkins, P. B., S. A. Wrighton, E. G. Schuetz, D. T. Molowa, and P. S.
Guzelian. 1987. Identification of glucocorticoid-inducible cytochromes
P-450 in the intestinal mucosa of rats and man. J. Clin. Investig. 80:1029–
1036.
26. WHO. 2005. WHO world malaria report. WHO, Geneva, Switzerland.
27. Wiesner, J., K. Fucik, K. Kettler, J. Sakowski, R. Ortmann, H. Jomaa, and
3670 VAN VOORHIS ET AL. ANTIMICROB. AGENTS CHEMOTHER.
 o
n
 August 1, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
M. Schlitzer. 2003. Structure-activity relationships of novel anti-malarial
agents. Part 6. N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophe-
nyl)-2-furyl]acrylic acid amides. Bioorg. Med. Chem. Lett. 13:1539–1541.
28. Wiesner, J., K. Kettler, J. Sakowski, R. Ortmann, A. M. Katzin, E. A.
Kimura, K. Silber, G. Klebe, H. Jomaa, and M. Schlitzer. 2004. Farnesyl-
transferase inhibitors inhibit the growth of malaria parasites in vitro and in
vivo. Angew. Chem. Int. Ed. Engl. 43:251–254.
29. Wiesner, J., A. Mitsch, M. Altenkamper, R. Ortmann, H. Jomaa, and M.
Schlitzer. 2003. Structure-activity relationships of novel anti-malarial agents.
Part 8. Effect of different central aryls in biarylacryloylaminobenzophenones
on antimalarial activity. Pharmazie 58:854–856.
30. Wiesner, J., R. Ortmann, H. Jomaa, and M. Schlitzer. 2003. New antima-
larial drugs. Angew. Chem. Int. Ed. Engl. 42:5274–5293.
31. Wiesner, J., R. Ortmann, A. Mitsch, P. Wissner, I. Sattler, H. Jomaa, and M.
Schlitzer. 2003. Inhibitors of farnesyltransferase: 5-arylacryloylaminobenzo-
phenones show antimalarial activity. Pharmazie 58:289–290.
VOL. 51, 2007 P. FALCIPARUM FARNESYLTRANSFERASE INHIBITORS 3671
 o
n
 August 1, 2019 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
